Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 3.6 %

NYSE BTX opened at $0.26 on Monday. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The stock has a market cap of $15.40 million, a P/E ratio of -0.12 and a beta of 4.61. The company’s 50-day simple moving average is $0.76 and its 200 day simple moving average is $1.36.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.